Update on platelet glycoprotein IIb/IIIa inhibitors: Recommendations for clinical practice

Therapeutic Advances in Cardiovascular Disease

Volumn 7, Issue 4, 2013, Pages 197-213

  Muñiz Lozano, Ana ^a   Rollini, Fabiana ^a   Franchi, Francesco ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

acute coronary syndrome; antiplatelet therapy; percutaneous coronary interventions

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; TICAGRELOR; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CORONARY STENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; LOADING DRUG DOSE; MOLECULAR WEIGHT; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANTIPLATELET THERAPY; PERCUTANEOUS CORONARY INTERVENTIONS;

ACUTE CORONARY SYNDROME; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 84880745523     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944713487781     Document Type: Article

References (73)

1. Akerblom A. James S. Koutouzis M. Lagerqvist B. Stenestrand U. Svennblad B. et al. (2010) Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol 56: 470–475.
2. Angiolillo D. Firstenberg M. Price M. Tummala P. Hutyra M. Welsby I. et al. (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307: 265–274.
3. Angiolillo D. Ueno M. Goto S. (2010) Basic principles of platelet biology and clinical implications. Circ J 74: 597–607.
4. Bhatt D. Topol E. (2000) Current role of platelet glycoprotein IIb / IIIa inhibitors in acute coronary syndromes. JAMA 284: 1549–1558.
5. Biondi-Zoccai G. Sciahbasi A. Bodí V. Fernández-Portales J. Kanei Y. Romagnoli E. et al. (2011) Right versus left radial artery access for coronary procedures: an international collaborative systematic review and meta-analysis including 5 randomized trials and 3210 patients. Int J Cardiol 20 December (Epub ahead of print).
6. Boersma E. Harrington R. Moliterno D. White H. Théroux P. van de Werf F. et al. (2002) Platelet glycoprotein IIb / IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359: 189–198.
7. Boersma E. Simoons M. (1997) Reperfusion strategies in acute myocardial infarction. Eur Heart J 18: 1703–1711.
8. Braunwald E. Angiolillo D. Bates E. Berger P. Bhatt D. Cannon C. et al. (2008) Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol 31: 2–9.
9. CAPTURE Study Investigators (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349: 1429–1435.
10. Chew D. Bhatt D. Sapp S. Topol E. (2001) Increased mortality with oral platelet glycoprotein IIb / IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103: 201–206.
11. Coller B. (1985) A new murine monoclonal antibody reports an activation-dependent change in the conformation and / or microenvironment of the platelet glycoprotein IIb / IIIa complex. J Clin Invest 76: 101–108.
12. Coller B. Peerschke E. Scudder L. Sullivan C. (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and / or IIIa. J Clin Invest 72: 325–338.
13. Cuisset T. Frere C. Quilici J. Morange P. Mouret J. Bali L. et al. (2008) Glycoprotein IIb / IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 1: 649–653.
14. Dangas G. Claessen B. Mehran R. Brener S. Brodie B. Dudek D. et al. (2012) Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 59: 1752–1759.
15. Davì G. Patrono C. (2007) Platelet activation and atherothrombosis. N Engl J Med 357: 2482–2494.
16. de Luca G. Navarese E. Cassetti E. Verdoia M. Suryapranata H. (2011) Meta-analysis of randomized trials of glycoprotein IIb / IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol 107: 198–203.
17. de Luca G. Suryapranata H. Stone G. Antoniucci D. Tcheng J. Neumann F. et al. (2005) Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293: 1759–1765.
18. de Luca G. Ucci G. Cassetti E. Marino P. (2009) Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 53: 1668–1673.
19. de Luca G. Verdoia M. Suryapranata H. (2012) Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis 222: 426–433.
20. Eitel I. Franke A. Schuler G. Thiele H. (2010) ST-segment resolution and prognosis after facilitated versus primary percutaneous coronary intervention in acute myocardial infarction: a meta-analysis. Clin Res Cardiol 99: 1–11.
21. Ellis S. Tendera M. de Belder M. van Boven A. Widimsky P. Janssens L. et al. (2008) Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358: 2205–2217.
22. EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb / IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330: 956–961.
23. EPILOG Investigators (1997) Platelet glycoprotein IIb / IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336: 1689–1696.
24. EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352: 87–92.
25. ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356: 2037–2044.
26. Freedman J. (2005) Molecular regulation of platelet-dependent thrombosis. Circulation 112: 2725–2734.
27. Fung A. Saw J. Starovoytov A. Densem C. Jokhi P. Walsh S. et al. (2009) Abbreviated infusion of eptifibatide after successful coronary intervention: the BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol 53: 837–845.
28. Giugliano R. White J. Bode C. Armstrong P. Montalescot G. Lewis B. et al. (EARLY ACS Investigators) (2009) Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360: 2176–2190.
29. Gu Y. Kampinga M. Wieringa W. Fokkema M. Nijsten M. Hillege H. et al. (2010) Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) trial. Circulation 122:2019–2027.
30. Halim S. Rao S. (2011) Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes. Curr Drug Targets 12: 1831–1835.
31. Hamm C. Bassand J. Agewall S. Bax J. Boersma E. Bueno H. et al. (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32: 2999–3054.
32. Hamm C. Heeschen C. Goldmann B. Vahanian A. Adgey J. Miguel C. et al. (1999) Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study. N Engl J Med 340: 1623–1629.
33. Heeschen C. Hamm C. Goldmann B. Deu A. Langenbrink L. White H. (1999) Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study. Lancet 354: 1757–1762.
34. Herrmann H. Lu J. Brodie B. Armstrong P. Montalescot G. Betriu A. et al. (2009) Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv 2: 917–924.
35. Jneid H. Anderson J. Wright R. Adams C. Bridges C. Casey D. et al. (2012) 2012 ACCF / AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation / American Heart Association Task Force on practice guidelines. Circulation 126: 875–910.
36. Kastrati A. Mehilli J. Neumann F. Dotzer F. ten Berg J. Bollwein H. et al. (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295: 1531–1538.
37. Kastrati A. Mehilli J. Schuhlen H. Dirschinger J. Dotzer F. ten Berg J. et al. (2004) A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350: 232–238.
38. Kastrati A. Neumann F. Schulz S. Massberg S. Byrne R. Ferenc M. et al. (2011) Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. ISAR REACT 4 trial. N Engl J Med 365: 1980–1989.
39. Kereiakes D. Kleiman N. Ambrose J. Cohen M. Rodriguez S. Palabrica T. et al. (1996) Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb / IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 27: 536–542.
40. Levine G. Bates E. Blankenship J. Bailey S. Bittl J. Cercek B. et al. (2011) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary. A report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58: 2550–25583.
41. Libby P. Theroux P. (2005) Pathophysiology of coronary artery disease. Circulation 111: 3481–3488.
42. Manoukian S. Feit F. Mehran R. Voeltz M. Ebrahimi R. Hamon M. et al. (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49: 1362–1368.
43. Mehilli J. Kastrati A. Schuhlen H. Dibra A. Dotzer F. von Beckerath N. et al. (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110: 3627–3635.
44. Mehilli J. Kastrati A. Schulz S. Frungel S. Nekolla S. Moshage W. et al. (2009) Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119: 1933–1940.
45. Mehran R. Lansky A. Witzenbichler B. Guagliumi G. Peruga J. Brodie B. et al. (2009 a) Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374: 1149–1159.
46. Mehran R. Pocock S. Stone G. Clayton T. Dangas G. Feit F. et al. (2009 b) Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30: 1457–1466.
47. O'Donoghue M. Antman E. Braunwald E. Murphy S. Steg P. Finkelstein A. et al. (2009) The efficacy and safety of prasugrel with and without a glycoprotein IIb / IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 54: 678–685.
48. Ottani F. La Vecchia L. de Vita M. Catapano O. Tarantino F. Galvani M. et al. (2010) Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 106: 167–174.
49. PRISM-PLUS Study Investigators (1998) Inhibition of the platelet glycoprotein IIb / IIIa receptor with tirofiban in unstable angina and non-Qwave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 338: 1488–1497.
50. PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb / IIIa with eptifibatide in patients with acute coronary syndromes: Platelet Glycoprotein IIb / IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339: 436–443.
51. Pytela R. Pierschbacher M. Ginsberg M. Plow E. Ruoslahti E. (1986) Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 231: 1559–1562.
52. Roffi M. Chew D. Mukherjee D. Bhatt D. White J. Heeschen C. et al. (2001) Platelet glycoprotein IIb / IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 104: 2767–2771.
53. Roffi M. Chew D. Mukherjee D. Bhatt D. White J. Moliterno D. et al. (2002) Platelet glycoprotein IIb / IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J 23: 1441–1448.
54. Savonitto S. D'Urbano M. Caracciolo M. Barlocco F. Mariani G. Nichelatti M. et al. (2010) Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ’bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 104: 285–291.
55. Simoons M. (2001) Effect of glycoprotein IIb / IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization. The GUSTO IV-ACS randomised trial. Lancet 357: 1915–1924.
56. Singla S. Sachdeva R. Uretsky B. (2012) The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention. J Am Coll Cardiol 60: 2005–2016.
57. Steg P. James S. Atar D. Badano L. Blömstrom-Lundqvist C. Borger M. et al. (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33: 2569–2619.
58. Stone G. Bertrand M. Moses J. Ohman E. Lincoff A. Ware J. et al. (2007) Routine upstream initiation vs. deferred selective use of glycoprotein IIb / IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 297: 591–602.
59. Stone G. Maehara A. Witzenbichler B. Godlewski J. Parise H. Dambrink J. et al. (2012) Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI trial. JAMA 307: 1817–1826.
60. Stone G. McLaurin B. Cox D. Bertrand M. Lincoff A. Moses J. et al. (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355: 2203–2216.
61. Stone G. Witzenbichler B. Guagliumi G. Peruga J. Brodie B. Dudek D. et al. (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358: 2218–2230.
62. Stone G. Witzenbichler B. Guagliumi G. Peruga J. Brodie B. Dudek D. et al. (2011) Heparin plus a glycoprotein IIb / IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 377: 2193–2204.
63. Thiele H. Wöhrle J. Hambrecht R. Rittger H. Birkemeyer R. Lauer B. et al. AIDA STEMI Trial Team (2012) Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 379: 923–931.
64. Topol J. GUSTO V Investigators (2001 a) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb / IIIa inhibition: the GUSTO V randomised trial. Lancet 357: 1905–1914.
65. Topol E. Byzova T. Plow E. (1999) Platelet GP IIb-IIIa blockers. Lancet 353: 227–231.
66. Topol E. Moliterno D. Herrmann H. Powers E. Grines C. Cohen D. et al. (2001 b) Comparison of two platelet glycoprotein IIb / IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344: 1888–1894.
67. Valgimigli M. Biondi-Zoccai G. Tebaldi M. van't Hof A. Campo G. Hamm C. et al. (2010) Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J 31: 35–49.
68. Valgimigli M. Campo G. de Cesare N. Meliga E. Vranckx P. Furgieri A. et al. (2009) Intensifying platelet inhibition with yirofiban in poor responders to ASA, clopidogrel, or both agents undergoing elective coronary intervention: results from the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to ASA and / or Resistance to Clopidogrel Study. Circulation 119: 3215–3222.
69. Valgimigli M. Tebaldi M. Campo G. Gambetti S. Bristot L. Monti M. et al. (2012) Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By Dropping or Shortening Infusion Line in Patients with ST-segment Elevation Myocardial Infarction Compared to or on top of Prasugrel given at Loading Dose) trial. JACC Cardiovasc Interv 5: 268–277.
70. Wagner C. Mascelli M. Neblock D. Weisman H. Coller B. Jordan R. et al. (1996) Analysis of GP IIb / IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 88: 907–914.
71. Wallentin L. Becker R. Budaj A. Cannon C. Emanuelsson H. Held C. et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045–1057.
72. Wijns W. Kolh P. Danchin N. Di Mario C. Falk V. Folliguet T. et al. (2010) Guidelines on myocardial revascularization. Eur Heart J 31: 2501–2555.
73. Wiviott S. Braunwald E. McCabe C. Montalescot G. Ruzyllo W. Gottlieb S. et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001–2015.